AN2 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-34.55	-35.17	-51.32	-64.73	-40.96	-21.54
Stock-Based Compensation	5.66	6.25	8.34	8.41	4.39	0.97
Other Adjustments	-0.71	-1.07	-3.28	-2.8	-0.62	0.05
Changes in Accounts Payable	-0.46	-0.3	0.64	0.55	2.5	0.42
Changes in Accrued Expenses	-2.19	-1.66	-4.57	5.69	2.98	1
Changes in Other Operating Activities	0.8	2.12	0.93	-0.41	-1.76	-1.39
Operating Cash Flow	-31.28	-29.83	-49.26	-53.29	-33.46	-20.48
Purchases of Investments	-26.59	-46.19	-46.75	-132.18	-93.84	-77.27
Proceeds from Sale of Investments	53.99	74.5	101.34	88.9	72.07	27.25
Investing Cash Flow	27.41	28.31	54.59	-43.28	-21.77	-50.02
Issuance of Common Stock	0.11	0.11	0.37	84.99	70.37	0.01
Repurchase of Common Stock	-	-	-	-	-0.01	-
Net Common Stock Issued (Repurchased)	0.11	0.11	0.37	84.99	70.36	0.01
Issuance of Preferred Stock	-	-	-	-	-	79.73
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	79.73
Other Financing Activities	-	-	-	-	-	-1.21
Financing Cash Flow	37.38	0.11	0.37	84.99	70.36	78.54
Net Cash Flow	33.5	-1.41	5.7	-11.57	15.12	8.03
Free Cash Flow	-31.28	-29.83	-49.26	-53.29	-33.46	-20.48
Free Cash Flow Per Share	-1.00	-0.99	-1.65	-2.26	-2.18	-7.76
Levered Free Cash Flow	-36.4	-35.01	-54.32	-58.9	-39.06	-28.03
Unlevered Free Cash Flow	-38.97	-37.95	-59.78	-63.8	-38.54	-21.54

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q